- Home
- VKTX vs FSK Comparison
VKTX vs FSK Comparison
Compare VKTX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VKTX | FSK |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | VKTX | FSK |
|---|---|---|
| Price | $34.04 | $14.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 6 |
| Target Price | ★ $87.07 | $17.33 |
| AVG Volume (30 Days) | ★ 3.3M | 2.5M |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 19.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | N/A | ★ $1,578,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.92 | $14.05 |
| 52 Week High | $43.15 | $24.10 |
Technical Indicators
Market Signals| Indicator | VKTX | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 42.94 |
| Support Level | $29.54 | $14.31 |
| Resistance Level | $36.00 | $14.74 |
| Average True Range (ATR) | 1.98 | 0.30 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 59.83 | 40.72 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.